InvestorsHub Logo
icon url

bennyboy1

12/21/19 10:42 AM

#225896 RE: Jonjones325 #225894

Jonjones325: SUCCESS is just ahead of us! Don't even think anything differently. The past is gone forever. No one has had any success in the CNS space for a long long time! This time little ANAVEX will slay the dragon. We definitely would not be moving forward if we didn't have success. WE WILL WIN the CNS marathon in astonishing results!!!!! This is OUR TIME!!!!! God Bless all of us and ANAVEX and all it stands for-AMEN!!!!
icon url

polarbear77

12/21/19 2:11 PM

#225922 RE: Jonjones325 #225894

I concur. IMO if the ceo/board had significant concerns or doubts about the operative question (after YEARS of analysis and results and multiple positive peer reviewed MOA pubs and safety/RWE data), then I do not think we’d be going it alone through our ph3 or spending our capital on NUMEROUS concurrent trials with the same 2-73 compound; all while shunning any development partnership offers.

Many would sell out early or would accept a punitive partnership deal in this historically-failure-prone CNS space UNLESS.................


Disclaimer: We’ve no guarantees of success. We shall only invest what we can afford to lose.

GLTY







icon url

drv17

12/21/19 9:02 PM

#225968 RE: Jonjones325 #225894

Jon Jones You stated in part "By now Missling and the gang know what we have." I would pssibly state this a little differently.
About 4 or 5 years Dr. Missling had met wuth a congressional committee and in that meeting he stated (to paraphrase) "We know what we have and we have no fear" or something to that effect.
A couple years later he said again to paraphrase " As this is getting bigger it is getting much more complicated"
My take is all of the delays were created by the fact that this has become much larger than Anavex even envisioned at the early stages.
I think Dr. Missling. management team , and the SAB have done a masterful job of playing three dimensional chess and have brought us to this point of last moves before the capture.